EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type

Corey J Hayes iD, Rebecca A Raciborski iD, Matthew Nowak, Mahip Acharya, Edward V Nunes iD, T John Winhusen iD

Addiction · 2025

DOI: 10.1111/add.16659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction, 2025. Verfasst von Corey J Hayes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Hauptthemen laut MEDLINE: Veterans, Opioid-Related Disorders, Naltrexone, Buprenorphine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HSRD VA, NIDA NIH HHS, National Institute on Drug Abuse of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study: (1) estimated the effect of early discontinuation of medication for opioid use disorder (MOUD) on overdose probability and (2) measured the relationship between patient characteristics and early discontinuation probability for each MOUD type. Design, setting and participants This was a retrospective cohort using electronic health record data from the US Veterans Healthcare Administration. Participants were veterans initiating MOUD with buprenorphine (BUP), methadone (MET) or extended‐release naltrexone (XR‐NTX) from fiscal years 2012–19. A total of 39 284 veterans met eligibility with 22 721 (57.8%) initiating BUP, 12 652 (32.2%) initiating MET and 3911 (10.0%) initiating XR‐NTX.

Measurements

Measurements (1) determined whether the veteran experienced an overdose in the 365 days after MOUD initiation (primary) and (2) early discontinuation of MOUD, defined as discontinuation before 180 days (secondary). We assumed that unobserved patient characteristics would jointly influence the probability of discontinuation and overdose. and estimated the joint distribution with a bivariate probit model.

Findings

We found that 9.0% of BUP initiators who experienced an overdose above the predicted 3.9% had no veteran‐discontinued BUP early; findings for XR‐NTX were similar, with 12.2% of initiators overdosing above the predicted 4.5%, but this was statistically inconclusive. We found no relationship between early discontinuation and overdose for MET initiators, probably due to the high risk of both events. The patient characteristics included in our post‐estimation exploratory analysis of early discontinuation varied by MOUD type, with between 14 (XR‐NTX) and 25 (BUP) tested. The only characteristics with at least one level showing a statistically significant change in probability of early discontinuation for all three MOUD types were geography and prior‐year exposure to psychotherapy, although direction and magnitude varied.

Conclusion

Early discontinuation of buprenorphine, and probably extended‐release naltrexone, appears to be associated with a greater probability of experiencing a fatal or non‐fatal overdose among US veterans receiving medication for opioid use disorder (MOUD); methadone does not show the same association. There is no consistent set of characteristics among early discontinuers by MOUD type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VeteransOpioid-Related DisordersNaltrexoneBuprenorphineMethadoneOpiate Substitution TreatmentNarcotic AntagonistsDrug OverdoseHumansMaleUnited StatesFemaleRetrospective StudiesAdultMiddle AgedDelayed-Action PreparationsAnalgesics, OpioidCohort StudiesOpiate Overdose

Stichwörter der Autor:innen

Geographic disparitiesmedication treatment for opioid use disorderopioid use disorderoverdoseracial disparitiesveterans

Substanzen

NaltrexoneBuprenorphineMethadoneNarcotic AntagonistsDelayed-Action PreparationsAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Institute for Digital Health and Innovation, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System, North Little Rock, AR, USA.
  • Behavioral Health Quality Enhancement Research Initiative, Central Arkansas Veterans Healthcare System, North Little Rock, AR, USA.
  • Evidence, Policy, and Implementation Center, Central Arkansas Veterans Healthcare System, North Little Rock, AR, USA.
  • College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

ORCID-Profile: Corey J Hayes, Rebecca A Raciborski, Edward V Nunes, T John Winhusen

Förderung

  • HSRD VA
  • NIDA NIH HHS
  • National Institute on Drug Abuse of the National Institutes of Health
  • VA Health Services Research
  • National Drug Abuse Treatment Clinical Trials Network
  • Health Services Research and Development

Zitieren

APA

Hayes, C. J., Raciborski, R. A., Nowak, M., Acharya, M., Nunes, E. V., & Winhusen, T. J. (2025). Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Addiction. https://doi.org/10.1111/add.16659

Vancouver

Hayes CJ, Raciborski RA, Nowak M, Acharya M, Nunes EV, Winhusen TJ. Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Addiction. 2025. doi:10.1111/add.16659

BibTeX
@article{Hayes2025,
  author = {Hayes, Corey J and Raciborski, Rebecca A and Nowak, Matthew and Acharya, Mahip and Nunes, Edward V and Winhusen, T John},
  title = {Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type},
  journal = {Addiction},
  year = {2025},
  doi = {10.1111/add.16659}
}
Kostenlos starten →